Patents Issued in February 28, 2008
-
Publication number: 20080050392Abstract: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation.Type: ApplicationFiled: January 22, 2007Publication date: February 28, 2008Inventors: Epshtein Iliich, Shtark Borisovich, Kolyadko Suikhailovna
-
Publication number: 20080050393Abstract: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.Type: ApplicationFiled: November 22, 2002Publication date: February 28, 2008Inventors: Y. Tom Tang, Vinod Asundi, Dennis Ballinger, Ivan Labat, Dena Leshkowitz, Jin Liu, Deborah Loeb, Julia R. Montgomery, Ann M. Pace, James P. Sheridan, Radoje T. Drmanac
-
Publication number: 20080050394Abstract: A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge means for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second plunger and at least one microtubule member containing one of a treatment agent and a vaccine antigen. At least one open end formed within the at least one microtubule member for drawing a portion of the buffy coat therein and exposing the buffy coat to one of the treatment agent and vaccine antigen. A second needle capable of being attached onto the second syringe for introducing the exposed sample into the individual to effect treatment/vaccination thereof. This system is capable of allowing a plurality of treatment agents and/or vaccine antigens to be simultaneously applied to an individual.Type: ApplicationFiled: August 22, 2006Publication date: February 28, 2008Inventor: David R. Nalin
-
Publication number: 20080050395Abstract: Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based and the delivery method involves administering a vaccine, including an antigen and the adjuvant, to a mucosal surface.Type: ApplicationFiled: October 30, 2007Publication date: February 28, 2008Inventor: Jay GERBER
-
Publication number: 20080050396Abstract: The present invention relates to proteins belonging to the Bcl-2 family and peptides fragments thereof for use in pharmaceutical compositions. The disclosed proteins and peptide fragments are in particularly useful in vaccine compositions for treatment of cancer. The invention furthermore relates to methods of treatment using said compositions. It is also an aspect of the invention to provide T-cells and T-cell receptors specifically recognising the disclosed proteins and peptide fragments.Type: ApplicationFiled: November 18, 2004Publication date: February 28, 2008Applicant: Survac ApSInventors: Mads Hald Andersen, Per Thor Straten
-
Publication number: 20080050397Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a core peptide composed of Lys-Gly repeats.Type: ApplicationFiled: March 29, 2005Publication date: February 28, 2008Inventors: Walter Gerhard, Laszlo Otvos
-
Publication number: 20080050398Abstract: The invention relates to compositions comprising at least one peptide with a structure or structural pattern of ?-defensin 2 and/or its derivatives, especially human ?-defensin 2. The compositions are selected in particular from cosmetic and/or pharmaceutical compositions, cleaning and/or washing agents, water-treatment agents and cooling lubricants. The invention also relates to the use of peptides with a structure or structural pattern of ?-defensin 2 and/or its derivatives, especially human ?-defensin 2, as an antimicrobial active ingredient in the aforementioned agents.Type: ApplicationFiled: September 28, 2007Publication date: February 28, 2008Inventors: Dirk Bockmuehl, Heide-Marie Hoehne
-
Publication number: 20080050399Abstract: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can be joined to a stress protein by chemical conjugation or noncovalently using linking moieties, or by fusion (e.g., a recombinant fusion protein). Also described are expression vectors containing sequences encoding HPV antigens and stress proteins, which can be introduced into cells of a subject or cells ex vivo. Also described are compositions that include a stress protein linked to an HPV antigen and another pharmacologically acceptable component and stress protein —HPV antigen fusions and conjugates. These compositions can be used to induce or enhance an immune response against HPV and cells that exhibit HPV antigens, including HPV-associated tumors.Type: ApplicationFiled: July 26, 2007Publication date: February 28, 2008Inventors: Lee Mizzen, N. Chu, Huacheng Wu
-
Publication number: 20080050400Abstract: A method of developing seedlings includes germinating the seeds and air pruning the seedlings to a depth of about 3 inches.Type: ApplicationFiled: April 2, 2007Publication date: February 28, 2008Inventors: Wayne Lovelace, Hugh Steavenson, Bob Suddarth
-
Publication number: 20080050401Abstract: The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promotor or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. Furthermore, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention.Type: ApplicationFiled: December 22, 2005Publication date: February 28, 2008Inventors: Emmie De Wit, Monique Spronken, Ron Fouchier, Albert Osterhaus
-
Publication number: 20080050402Abstract: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating an immune response against influenza virus, methods of interfering with influenza virus replication, and methods of treating and preventing influenza virus infection are described.Type: ApplicationFiled: June 11, 2007Publication date: February 28, 2008Inventors: Yan Zhou, Yeun-Kyung Shin, Lorne Babiuk, Qiang Liu
-
Publication number: 20080050403Abstract: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle. The invention also provides a method for selective propagation of a set of virus particles, such as influenza virus particles present in an influenza isolate, which have an affinity for receptors comprising a specific glycosylation residue.Type: ApplicationFiled: July 16, 2007Publication date: February 28, 2008Inventors: Giuseppe Marzio, Maria Pau, Dirk Opstelten, Alphonsus Gerardus Uytdehaag
-
Publication number: 20080050404Abstract: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.Type: ApplicationFiled: October 31, 2007Publication date: February 28, 2008Inventor: Eric First
-
Publication number: 20080050405Abstract: A ringworm vaccine is disclosed comprising antigen isolated from at least one dermatophyte and a suitable carrier. The “antigen” can include a single antigen from a dermatophyte or a plurality of antigens as long as at least one antigen is included which will produce a sufficient immune response to confer resistance to ringworm infection upon the recipient of the vaccine. The antigen can also be isolated from more than one dermatophyte. If a preparation from more than one dermatophyte is made the antigen can include antigens which are common to all species of dermatophytes employed and/or antigens which are only specific to certain species. A method of producing such a ringworm vaccine is also disclosed. The method comprises making an antigen preparation comprising the dermatophyte antigen described above and combining the antigen preparation with a suitable carrier.Type: ApplicationFiled: August 17, 2007Publication date: February 28, 2008Applicant: Jefferson LabsInventors: Mark Werner, Michael Strobel
-
Publication number: 20080050406Abstract: The present invention provides a modified Dermatophagoides pteronyssinus allergen Der p 5 protein which has ability to inhibit IgE binding when exposed against to the antigen. A method for treating allergy comprising administrating a therapeutically effective dose of the modified D. pteronyssinus allergen Der p 5 protein to a subject suffering from allergy Der p 5 is also provided.Type: ApplicationFiled: July 17, 2007Publication date: February 28, 2008Applicant: GenMont Biotech Inc.Inventors: Ching-Hsiang Hsu, Wei-Chih Su
-
Publication number: 20080050407Abstract: Oral products for the improved mineralization/remineralization of teeth are provided. In an embodiment, the present disclosure provides an oral product comprising a calcium salt, a phosphate salt, a sodium salt and a potassium salt. For example, the molar ratio of the sodium salt to the potassium salt ranges from about 3 to about 4.Type: ApplicationFiled: February 2, 2007Publication date: February 28, 2008Inventor: Michael Haas
-
Publication number: 20080050408Abstract: A whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be a one-component or a two-component composition. The system may also be an unfoamed, a foamed or a foamable composition. For a one-component system, a sparingly soluble calcium phosphate salt may be in dry particle form with at least one gelling agent, wherein the salt is capable of sustained release of both calcium and phosphate ions into saliva upon exposure of the particle thereto and providing a hydroxyapatite remineralization. In a two component system, a first component has at least one peroxide compound, at least one source of phosphate and at least one gelling agent; and a second component has at least one source of calcium, strontium and/or mixtures thereof. The second component may also contain at least one gelling agent, and the composition maybe present as a foam or is foamable. The composition may be packed in a two-compartment syringe, or be present in a carrier or coated onto a substrate.Type: ApplicationFiled: October 29, 2007Publication date: February 28, 2008Applicant: DISCUS DENTAL, LLCInventors: Robert Hayman, Nancy Quan, Jeff MacDonald
-
Publication number: 20080050409Abstract: A clear, water based, homogeneous insect repellent sunscreen composition, comprising an oil soluble hydrophobic sunscreen component, an amido insect repellent component, an alcohol component, and water.Type: ApplicationFiled: August 25, 2006Publication date: February 28, 2008Inventors: Andrew H. Pechko, Vincent T. Polywoda
-
Publication number: 20080050410Abstract: The present invention is directed toward a self-decontaminating surface coating, which when cured has a partially hydrophobic surface. The coating comprises a polymeric coating resin which, when cured, is hydrophilic. The coating also comprises a biocide, a germinating agent, and a hydrophobic micro/nano particulate material. The coating is suitable for application to ceramics, metals, and polymer substrates. Articles coated with the coating of the present invention are resistant to spores.Type: ApplicationFiled: October 11, 2006Publication date: February 28, 2008Applicants: LUNA INNOVATIONS INCORPORATED, THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE NAVYInventors: Martin Rogers, Janice Phillips, Bryan Koene, Marc Hirsch, James Wynne
-
Publication number: 20080050411Abstract: The present invention is a game attractant comprised of a mixture of rice bran, wheat bran and dried molasses to attract the attention of ungulates and avian fauna. By the incorporation of these three ingredients, the nutritional and vitamin value is elevated above the natural diet of the fauna. Therefore once expelled in pyramid form upon the intended-sight, the animals are attracted to the richness of this mix.Type: ApplicationFiled: August 28, 2006Publication date: February 28, 2008Inventor: Jonathan David Rudd
-
Publication number: 20080050412Abstract: A method of building an orthopedic implant including the steps of mixing a powder having antimicrobial properties with a biocompatible powder to form a mixture. Next, the mixture is deposited on top of a substrate. The substrate may be part of the finished product or only a work platform. The mixture layer is then selectively melted.Type: ApplicationFiled: August 15, 2006Publication date: February 28, 2008Applicant: Howmedica Osteonics Corp.Inventors: Eric Jones, Aiguo Wang
-
Publication number: 20080050413Abstract: A stent is provided with a composition which includes melatonin and paclitaxel for use in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.Type: ApplicationFiled: August 23, 2006Publication date: February 28, 2008Inventors: Ronald Adrianus Maria Horvers, Eveline Van Oosterhout
-
Publication number: 20080050414Abstract: Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders.Type: ApplicationFiled: April 27, 2005Publication date: February 28, 2008Inventors: Howard Elford, Arturo Cardounel
-
Publication number: 20080050415Abstract: According to an aspect of the invention, implantable or insertable medical devices are provided, which contain one or more composite regions. These composite regions, in turn, contain (a) a polymeric component comprising a vinyl aromatic polymer and (b) a ceramic component comprising a metal or semi-metal oxide.Type: ApplicationFiled: June 1, 2007Publication date: February 28, 2008Inventors: Liliana Atanasoska, Michele Zoromski, Robert Warner, Steve Kangas
-
Publication number: 20080050416Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: ApplicationFiled: September 12, 2007Publication date: February 28, 2008Applicant: Searete LLC,Inventors: Ed Harlow, Roderick Hyde, Edward Jung, Robert Langer, Eric Leuthardt, Lowell Wood
-
Publication number: 20080050417Abstract: The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.Type: ApplicationFiled: June 13, 2007Publication date: February 28, 2008Applicant: FMC BIOPOLYMER ASInventors: Denis Dufrane, Pierre Gianello, Jan Melvik
-
Publication number: 20080050418Abstract: According to one aspect of the invention, medical devices are provided which contain the following: (a) an interior region that contains at least one degradation promoting agent and (b) an exterior region disposed over the interior region that contains at least one biodegradable polymer and at least one therapeutic agent.Type: ApplicationFiled: July 11, 2007Publication date: February 28, 2008Applicant: Boston Scientific Scimed, Inc.Inventors: Shrirang V. Ranade, Courtney Sikes, Mark Steckel
-
Publication number: 20080050419Abstract: The invention provides aliphatic epoxy-containing PEA polymer compositions with film-forming properties. The aliphatic epoxy di-acids used in the invention PEA compositions include non-toxic fatty aliphatic epoxy homologs. A second, C-protected L-lysine-based monomer can be introduced into the polymer to provide additional chain flexibility. The invention PEA polymer compositions are useful for delivery of bioactive agents when administered internally or used in the manufacture of implantable medical devices. Biodegradable hydrogels can be made using the invention epoxy-containing PEAs.Type: ApplicationFiled: August 16, 2007Publication date: February 28, 2008Applicant: MediVas, LLCInventors: Ramaz Katsarava, David Tugushi, Nino Zavradashvili, Zaza Gomurashvili
-
Publication number: 20080050420Abstract: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Type: ApplicationFiled: October 31, 2007Publication date: February 28, 2008Applicant: ALLERGAN, INC.Inventor: Vernon Wong
-
Publication number: 20080050421Abstract: Drug delivery devices for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.Type: ApplicationFiled: October 31, 2007Publication date: February 28, 2008Applicant: ALLERGAN, INC.Inventor: Vernon Wong
-
Publication number: 20080050422Abstract: The invention relates to a fast-dissolving film product containing at least one drug; and a water soluble polymer composition. The invention further relates to methods of administering the film product. The method includes administering the film to the oral cavity of a subject in need of the drug; and administering a fluid in the oral cavity while the film is present therein to substantially dissolve the film and form a solution or dispersion thereof to be ingested by the subject. Desirably, ingestion of the thus-formed solution or dispersion provides increased blood levels of the drug as compared to the film taken without the fluid.Type: ApplicationFiled: September 26, 2006Publication date: February 28, 2008Inventors: Garry L. Myers, Richard C. Fuisz
-
Publication number: 20080050423Abstract: The present invention discloses a biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet comprising a monolayer of interconnected HCECs with substantially uniform orientation, wherein the bioengineered cell sheet is attached to a surface of the carrier with apical surfaces of the HCECs facing said carrier.Type: ApplicationFiled: August 23, 2006Publication date: February 28, 2008Applicant: National Tsing Hua UniversityInventors: Ging-Ho Hsiue, Jui-Yang Lai
-
Publication number: 20080050424Abstract: A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase dissolving capacity of the matrix for the active substance.Type: ApplicationFiled: October 31, 2007Publication date: February 28, 2008Inventors: Walter Muller, James Peck
-
Publication number: 20080050425Abstract: The present invention relates to methods for treating cancer comprising administering a combination of 5-fluorouracil or a derivative thereof and a liposomal platinum complex. Pharmaceutical compositions comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex, and kits comprising unit doses of 5-fluorouracil or a derivative thereof and liposomal platinum complex.Type: ApplicationFiled: May 20, 2003Publication date: February 28, 2008Inventors: Jonathan Lewis, Axel Hoos, Robert Peter Gale
-
Publication number: 20080050426Abstract: The present invention relates to a method for preparing purified extract from wild ginseng showing anticancer activity such as inhibitory of cancer cell adherence, inhibitory of cancer cell metastasis and immunostimulating effect and a composition comprising the same prepared by inventive method. The composition have potent anticancer activity, therefore, it can be used as the therapeutics for treating and preventing various cancer diseases.Type: ApplicationFiled: August 2, 2004Publication date: February 28, 2008Applicant: SEOCKSANTEO MEDICAL CO., LTD.Inventors: Yong Park, In Sop Shim, Gyu Song
-
Publication number: 20080050427Abstract: Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof, said combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method of effectively treating pain in humans or other mammals, comprising administering to the patient a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof such that the dosing interval of the meloxicam overlaps with the dosing interval of the oxycodone, said combination in an amount sufficient to provide an analgesic effect in a human patient.Type: ApplicationFiled: July 10, 2007Publication date: February 28, 2008Applicant: Purdue Pharma L.P.Inventors: Ronald Burch, Paul Goldenheim, Richard Sackler
-
Publication number: 20080050428Abstract: The invention relates to novel extended release dosage forms for reversible proton pump antagonists comprising a basic excipient.Type: ApplicationFiled: September 30, 2005Publication date: February 28, 2008Applicant: Altana Pharma AGInventors: Hartmut Ney, Isabel Anstett-Klein, Simone Hiltl, Antje Brueck-Scheffler
-
Publication number: 20080050429Abstract: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.Type: ApplicationFiled: February 13, 2007Publication date: February 28, 2008Inventors: Jose Rocca, Eugenio Cefali, Yucun Zhu
-
Publication number: 20080050430Abstract: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC sufficient to achieve at least the minimum amount of bacterial eradication for treatment of said bacterial infection.Type: ApplicationFiled: May 7, 2007Publication date: February 28, 2008Inventors: Henry Flanner, Robert Guttendorf, Donald Treacy, Susan Clausen, Beth Burnside
-
Publication number: 20080050431Abstract: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: August 13, 2007Publication date: February 28, 2008Applicant: Penwest Pharmaceuticals Company.Inventors: Anand Baichwal, Huai-Hung Kao, Troy McCall
-
Publication number: 20080050432Abstract: The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are expressed at intervals. The formulation of the present invention comprises statin-based lipid-lowering agent and dihydropyridine-based calcium channel blocker that affects cytochrome P450 enzyme as active ingredients, and is such constituted that the release rates of the aforementioned ingredients are different, thus preventing antagonism and side effects, while maintaining the synergistic effect, which leads to the convenience in medication.Type: ApplicationFiled: April 5, 2007Publication date: February 28, 2008Inventors: Sung Soo Jun, Young Gwan Jo, Ja-Seong Koo, Jin Wook Kim, Ju-Bin Yim
-
Publication number: 20080050433Abstract: The invention relates to a water-soluble film for releasing active substances, particularly plant protection products and plant growth promoting substances. The water-soluble film can be defined with regard to its dimensions so that the content of the active substance can be exactly pre-dosed in such a defined film section. The release of the active substance or of the active substance combination from the water-soluble film ensues in a controlled manner by the action of water. The soil, standing and flowing water, surfaces of plants and other objects make up the environment.Type: ApplicationFiled: April 19, 2005Publication date: February 28, 2008Inventors: Michael Roreger, Qian-Yi Li, Malgorzata Kloczko, Iris Schnitzler
-
Publication number: 20080050434Abstract: Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizing agent; and other pharmaceutically acceptable excipients; and process for preparing such compositions are provided. Also provided is a method for the management/treatment of fungal, bacterial or microbial infections, inflammations, autoimmune conditions, or hormonal disorders which comprises administering a pharmaceutically effective amount of such pharmaceutical composition to a subject in need of such treatment. The compositions of the present invention are non-greasy and easily water washable, and provides an enhanced localization of hydrophobic and/or amphiphilic active ingredients on the skin.Type: ApplicationFiled: March 17, 2005Publication date: February 28, 2008Inventors: Rajesh Jain, Kour Chand, Sukhjeet Singh, Vaibhav Sihorkar
-
Publication number: 20080050435Abstract: The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly ploy (hydroxyalkyl (meth) acrylamide mono/di-lactate) interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention comprise monomers, which have modifiable functionality. The functionality of the monomers can for example be modified by the presence of hydrolysable groups. The modification is effected by the incubation, leading to a change of the water solubility characteristics of the polymer. The polymers used in the present invention contain hydrolysable chemical groups. As a result the polymer's solution characteristics, specifically its lower critical solution temperature (LCST), change upon incubation.Type: ApplicationFiled: March 17, 2005Publication date: February 28, 2008Inventors: Wilhelmus Everhardus Hennink, Cornelis Franciscus Van Nostrum, Marinus Jacob Van Steenbergen, Osamu Soga
-
Publication number: 20080050436Abstract: A minimally invasive method that allows for complete obliteration of the affected vessels without scarring or any of the other undesirable complications of conventional or foam sclerotherapy. More particularly, the present invention relates to a method for using a non-foaming thickener to reduce dilution and diffusion of the sclerosant in the blood vessel and enhance the efficacy of the sclerotherapy treatment. The thickener can be thickening agent, hydrogel, environmentally sensitive hydrogel, and self-assembly polymer, etc. After it is mixed with sclerosant and injected into the blood vessel through a needle or a catheter, the compound will replace blood and obliterate the affected vessels.Type: ApplicationFiled: August 25, 2006Publication date: February 28, 2008Inventor: Jack F. Chu
-
Publication number: 20080050437Abstract: A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents hydrogen, hydroxy, methoxy or ethoxy, and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable diluent or carrier; provided that the formulation may only contain iota-carageenan and a neutral gelling polymer when the compound of formula (I) is in the form of a salt; such formulations being of use for the treatment of a cardiovascular disorder.Type: ApplicationFiled: March 9, 2007Publication date: February 28, 2008Inventors: Anders Magnusson, Mikael Thune
-
Publication number: 20080050438Abstract: The object of the present invention is to provide a dry composition having the following advantageous properties. That is, even when left in a highly humid environment, the dry composition of the present invention scarcely loses its pharmacological activity, does not deliquesce and retains its dry state over a long period of time. A dry composition of the present invention comprises at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected from the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic tripeptides.Type: ApplicationFiled: September 7, 2006Publication date: February 28, 2008Inventors: Chikamasa Yamashita, Kazuya Sakata, Shinichi Ishikawa, Yuzo Kimura
-
Publication number: 20080050439Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.Type: ApplicationFiled: March 28, 2007Publication date: February 28, 2008Inventor: Alan Montgomery
-
Publication number: 20080050440Abstract: The present invention provides a plant epidemic prevention agent that allows for easily and efficiently decomposing and eliminating pathogenic germs that cause plant epidemic and effectively suppressing plant disease caused by the pathogenic germs and making diseased plants recover from the disease without adversely affecting the human body and allows for achieving environmental preservation; a plant epidemic prevention method and a plant epidemic prevention system using the plant epidemic prevention agent; plants and a plant cultivation method. The plant epidemic prevention agent contains at least a photocatalytic powder containing phosphorous or an apatite structure. The plant epidemic prevention method includes supplying the plant epidemic prevention agent to plants.Type: ApplicationFiled: July 27, 2007Publication date: February 28, 2008Applicants: FUJITSU LIMITED, THE UNIVERSITY OF TOKYOInventors: Masato WAKAMURA, Katsuhiro ATSUMA, Toshiya WATANABE, Naoya YOSHIDA
-
Publication number: 20080050441Abstract: The present invention provides a method of preparing a packed sterile solid active pharmaceutical ingredient, in particular sterile steroids such as a glucocorticosteroid acid.Type: ApplicationFiled: July 20, 2007Publication date: February 28, 2008Inventors: Enrico Bettetini, Piercorrado Bordoni, Francesca Cofano, Alfio Messina, Massimiliano Palladino